Kwo‐Chang Ueng

Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial

Kausik K Ray, Helen M Colhoun, Michael Szarek et al. · The Lancet Diabetes & Endocrinology · 2019 · 328 citations · Full text

Medicine, Cardiology, Internal Medicine +15

Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial

Deepak L. Bhatt, Philippe Gabríel Steg, Shamir R Mehta et al. · The Lancet · 2019 · 210 citations · Full text

Medicine, Cardiology, Pharmacotherapy +15

Lipid‐Lowering Effects of Curcumin in Patients with Metabolic Syndrome: A Randomized, Double‐Blind, Placebo‐Controlled Trial

Yi‐Sun Yang, Ying‐Fang Su, Hui‐Wen Yang et al. · Phytotherapy Research · 2014 · 199 citations

Medicine, Pharmacology, Pharmacotherapy +15

Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab

Emil Hagström, Philippe Gabríel Steg, Michael Szarek et al. · Circulation · 2022 · 122 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

2022 Guidelines of the Taiwan Society of Cardiology and the Taiwan Hypertension Society for the Management of Hypertension.

Tzung‐Dau Wang, Chern‐En Chiang, Ting‐Hsing Chao et al. · PubMed · 2022 · 117 citations · Full text

Medicine, Cardiology, Clinical Cardiology +16